Preliminary data on the use of a combined surgical-polychemical-immunoradiotherapy protocol in the treatment of 13 T2N2M0 lung cancer patients are reported. The results are compared with those obtained in a 13 patient control group, homogenous by histotype, stage and surgical treatment who were given no other therapy. At 24 months the average survival rate in the first group was 61.5% compared to 15.3% in the second. It was significant that survival at 24 months after pneumonectomy rose from 16.6% to 50% and even more significantly survival after lobectomy rose from 14.2% to 71.4%.
[Protocol of combined surgical and polychemico-immunoradiologic therapy of stage T2N2MO lung cancer] / Tosato, Filippo; M., Grande; M., Cassese; P., Paoletti; C., De Marchi; F., Scotto; C., Benvenuti; Paolini, Antonio. - In: MINERVA MEDICA. - ISSN 0026-4806. - 75:27(1984).
[Protocol of combined surgical and polychemico-immunoradiologic therapy of stage T2N2MO lung cancer].
TOSATO, Filippo;PAOLINI, Antonio
1984
Abstract
Preliminary data on the use of a combined surgical-polychemical-immunoradiotherapy protocol in the treatment of 13 T2N2M0 lung cancer patients are reported. The results are compared with those obtained in a 13 patient control group, homogenous by histotype, stage and surgical treatment who were given no other therapy. At 24 months the average survival rate in the first group was 61.5% compared to 15.3% in the second. It was significant that survival at 24 months after pneumonectomy rose from 16.6% to 50% and even more significantly survival after lobectomy rose from 14.2% to 71.4%.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
